CN Patent

CN112533602A — Axl激酶抑制剂及其用途

Assigned to Sumitomo Pharma Oncology Inc · Expires 2021-03-19 · 5y expired

What this patent protects

结构(I)的化合物的酒石酸盐，其结晶形式及其用于治疗实体肿瘤(例如晚期实体肿瘤)或造血系统癌症的治疗应用。本文还提供了合成所述酒石酸盐及其结晶形式的方法。

USPTO Abstract

结构(I)的化合物的酒石酸盐，其结晶形式及其用于治疗实体肿瘤(例如晚期实体肿瘤)或造血系统癌症的治疗应用。本文还提供了合成所述酒石酸盐及其结晶形式的方法。

Drugs covered by this patent

Patent Metadata

Patent number
CN112533602A
Jurisdiction
CN
Classification
—
Expires
2021-03-19
Drug substance claim
No
Drug product claim
No
Assignee
Sumitomo Pharma Oncology Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.